Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Sterility & contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections.

6,317 FDA drug recalls with this cause, newest first.

This is the single biggest cause in the register by a wide margin. It covers products that had to be sterile - injectables, eye drops, certain ointments - but could not be verified sterile, or were found contaminated during testing. Most of these recalls come from compounding pharmacies and outsourcing facilities after an FDA inspection finds gaps in how sterile products were made. Sterility failures are treated seriously because the products involved have the least room for error, going straight into the bloodstream or the eye.

Class II · Moderate risk

Multitrace-5 Concentrate

Lack of Assurance of Sterility: Park Compounding is recalling Methylcobalamin 5 mg/mL, Multitrace-5 Concentrate, and Testosterone Cypionate (sesame oil) for injection due to lack of sterility assurance.

Terminated Sterility / contamination South Coast Specialty Compounding, Inc. D-1026-2013
Class II · Moderate risk

Methylcobalamin Injection 5 mg/mL

Lack of Assurance of Sterility: Park Compounding is recalling Methylcobalamin 5 mg/mL, Multitrace-5 Concentrate, and Testosterone Cypionate (sesame oil) for injection due to lack of sterility assurance.

Terminated Sterility / contamination South Coast Specialty Compounding, Inc. D-1025-2013
Class II · Moderate risk

Diazepam Injection

Lack of assurance of sterility: ineffective crimp on fliptop vials that may result in leaking at the neck of the vials.

Terminated Sterility / contamination Hospira Inc. NDC 0409-3213-12 D-927-2013
Class II · Moderate risk

CARBOplatin Injection

Lack of Assurance of Sterility: The required reduction of endotoxin was not met during the annual revalidation of the vial washer.

Terminated Sterility / contamination Teva Pharmaceuticals USA, Inc. NDC 0703-3249-11 D-928-2013
Class II · Moderate risk

Sodium Hydroxide 10%

Lack of Assurance of Sterility; FDA inspectional findings resulted in concerns associated with quality control procedures that impacted sterility assurance

Terminated Sterility / contamination Beacon Hill Medical Pharmacy, P.C. D-999-2013
Class II · Moderate risk

Sodium Bicarbonate Pf 8.4% Injectable

Lack of Assurance of Sterility; FDA inspectional findings resulted in concerns associated with quality control procedures that impacted sterility assurance

Terminated Sterility / contamination Beacon Hill Medical Pharmacy, P.C. D-998-2013
Class II · Moderate risk

Sermorelin Acetate 10 Mg Injectable

Lack of Assurance of Sterility; FDA inspectional findings resulted in concerns associated with quality control procedures that impacted sterility assurance

Terminated Sterility / contamination Beacon Hill Medical Pharmacy, P.C. D-997-2013
Class II · Moderate risk

Selenium 400 Mcg/Ml Injectable

Lack of Assurance of Sterility; FDA inspectional findings resulted in concerns associated with quality control procedures that impacted sterility assurance

Terminated Sterility / contamination Beacon Hill Medical Pharmacy, P.C. D-996-2013
Class II · Moderate risk

Pumice/Lidocaine HCL 1.5%/1% Inj Susp

Lack of Assurance of Sterility; FDA inspectional findings resulted in concerns associated with quality control procedures that impacted sterility assurance

Terminated Sterility / contamination Beacon Hill Medical Pharmacy, P.C. D-993-2013
Class II · Moderate risk

Progesterone 50 Mg/Ml Oil Inj Soln

Lack of Assurance of Sterility; FDA inspectional findings resulted in concerns associated with quality control procedures that impacted sterility assurance

Terminated Sterility / contamination Beacon Hill Medical Pharmacy, P.C. D-992-2013
Class II · Moderate risk

Procaine P/F 20 Mg/Ml Injectable

Lack of Assurance of Sterility; FDA inspectional findings resulted in concerns associated with quality control procedures that impacted sterility assurance

Terminated Sterility / contamination Beacon Hill Medical Pharmacy, P.C. D-990-2013
Class II · Moderate risk

Potassium Chloride 2 Meq/Ml Injectable

Lack of Assurance of Sterility; FDA inspectional findings resulted in concerns associated with quality control procedures that impacted sterility assurance

Terminated Sterility / contamination Beacon Hill Medical Pharmacy, P.C. D-989-2013
Class II · Moderate risk

Paraben Water for Injection

Lack of Assurance of Sterility; FDA inspectional findings resulted in concerns associated with quality control procedures that impacted sterility assurance

Terminated Sterility / contamination Beacon Hill Medical Pharmacy, P.C. D-987-2013
Class II · Moderate risk

Oxytocin 10 Units/Ml

Lack of Assurance of Sterility; FDA inspectional findings resulted in concerns associated with quality control procedures that impacted sterility assurance

Terminated Sterility / contamination Beacon Hill Medical Pharmacy, P.C. D-986-2013
Class II · Moderate risk

Nalbuphine HCL 20 Mg/Ml Injectable

Lack of Assurance of Sterility; FDA inspectional findings resulted in concerns associated with quality control procedures that impacted sterility assurance

Terminated Sterility / contamination Beacon Hill Medical Pharmacy, P.C. D-983-2013
Class II · Moderate risk

Multitrace-5 Injectable

Lack of Assurance of Sterility; FDA inspectional findings resulted in concerns associated with quality control procedures that impacted sterility assurance

Terminated Sterility / contamination Beacon Hill Medical Pharmacy, P.C. D-982-2013